Market capitalization | $27.55m |
Enterprise Value | $65.61m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.51 |
P/S ratio (TTM) P/S ratio | 2.31 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -0.79% |
Revenue (TTM) Revenue | $11.91m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Accelerate Diagnostics, Inc. forecast:
2 Analysts have issued a Accelerate Diagnostics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 12 12 |
1%
1%
|
|
Gross Profit | 2.89 2.89 |
27%
27%
|
|
EBITDA | -35 -35 |
36%
36%
|
EBIT (Operating Income) EBIT | -38 -38 |
33%
33%
|
Net Profit | -53 -53 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.
Head office | United States |
CEO | Jack Phillips |
Employees | 134 |
Founded | 1982 |
Website | acceleratediagnostics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.